Angle's Parsortix system is strongest performer in German study

Parsortix out-performed all other systems on each investigated measure, leading it to be recommended by those undertaking the study that it was "the system to use" in patients that were afflicted with such renal cell carcinomas.

The detailed performance evaluation on the ability of four different systems to harvest circulating tumour cells (CTCs) for clear renal carcinoma (kidney cancer) patients was measured against antibody-based capture, density-based separation and centrifugation, and CD45 negative depletion.

Angle founder and chief executive, Andrew Newland, said, "This published study further demonstrates that the Parsortix system outperforms others for harvesting circulating tumour cells from the blood of cancer patients in the fast emerging liquid biopsy market."

"Angle's strategy of promoting research use sales to drive widespread adoption of its CTC harvesting system has now delivered a seventh positive peer-reviewed publication on the utility of the ParsortixTM system, this time in the renal cancer setting," he added.

Dr Christof Bernemann, laboratory head at the Clinic for Urology at University Hospital Muenster, said, "The number of studies reporting circulating tumour cell detection in clear cell renal cell carcinoma patients is small, reflecting the poor performance of the traditional antibody-based systems in isolating CTCs in this cancer type.

"We believe, therefore, that the outperformance of the Parsortix system we have demonstrated should boost research into this cancer, potentially enabling personalised cancer treatment in the future," he concluded.

As of 1200 BST, shares had seen a 6.75% bump to 42.70p.